- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04046939
Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma (EXHALE-1)
April 11, 2023 updated by: Knopp Biosciences
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Biomarker Study of the Effects of Dexpramipexole on Eosinophils in Subjects With Eosinophilic Asthma
This is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 12 weeks on peripheral blood eosinophil count in subjects with eosinophilic asthma.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
One hundred subjects will receive study drug or matching placebo over 12 weeks of consecutive dosing.
Following a short Run-in Period, eligible subjects will enter the Primary Assessment Period and receive twice-daily dosing of study drug or placebo for 12 weeks.
Following 12 weeks of treatment, subjects will enter a 12-week Eosinophil Recovery Period.
The primary endpoint for the study is the change in blood absolute eosinophil count from Baseline to Week 12.
Study Type
Interventional
Enrollment (Actual)
534
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Research Site
-
Mission Viejo, California, United States, 92691
- Research Site
-
Westminster, California, United States, 92683
- Research Site
-
-
Colorado
-
Denver, Colorado, United States, 80230
- Research Site
-
-
Florida
-
Daytona Beach, Florida, United States, 32117
- Research Site
-
Miami, Florida, United States, 33186
- Research Site
-
Orlando, Florida, United States, 32803
- Research Site
-
Tampa, Florida, United States, 33612
- Research Site
-
Tampa, Florida, United States, 33634
- Research Site
-
-
Georgia
-
Lawrenceville, Georgia, United States, 30046
- Research Site
-
Winder, Georgia, United States, 30680
- Research Site
-
-
Idaho
-
Boise, Idaho, United States, 83706
- Research Site
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48336
- Research Site
-
-
Minnesota
-
Plymouth, Minnesota, United States, 55441
- Research Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Research Site
-
Saint Louis, Missouri, United States, 63141
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89119
- Research Site
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Research Site
-
-
New York
-
Corning, New York, United States, 14830
- Research Site
-
New Hyde Park, New York, United States, 11042
- Research Site
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27607
- Research Site
-
Winston-Salem, North Carolina, United States, 27103
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45231
- Research Site
-
Cincinnati, Ohio, United States, 45242
- Research Site
-
Columbus, Ohio, United States, 43235
- Research Site
-
Dublin, Ohio, United States, 43016
- Research Site
-
-
Oklahoma
-
Edmond, Oklahoma, United States, 73034
- Research Site
-
-
Oregon
-
Medford, Oregon, United States, 97504
- Research Site
-
Portland, Oregon, United States, 97202
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15205
- Research Site
-
-
South Carolina
-
Anderson, South Carolina, United States, 29621
- Research Site
-
North Charleston, South Carolina, United States, 29406
- Research Site
-
-
Texas
-
Allen, Texas, United States, 75013
- Research Site
-
Boerne, Texas, United States, 78006
- Research Site
-
Dallas, Texas, United States, 75240
- Research Site
-
El Paso, Texas, United States, 79902
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 74 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female ≥18 and <75 years of age at the time of consent
- Physician diagnosis of asthma for ≥12 months (relative to Baseline) based on Global Initiative for Asthma (GINA) 2018 Guidelines
- Asthma requiring treatment with, at a minimum, low dose inhaled corticosteroids in combination with a long-acting β2 agonist, on a stable dose for at least 1 month before Screening
- Bronchodilator reversibility, as evidenced by ≥12% and ≥200 mL improvement in FEV1 15 to 25 minutes following inhalation of albuterol at Screening
- Pre-bronchodilator FEV1 ≥40% and <80% of predicted at Screening and Baseline
- AEC ≥0.30 x10^9/L at the Screening visit
- ACQ-7 ≥1.5 at Screening
- Negative pregnancy test at Baseline
- Adherence ≥85% with twice-daily placebo taken during the Run-in Period
Exclusion Criteria:
- Treatment for an asthma exacerbation within 8 weeks prior to Baseline visit
- Treatment with systemic corticosteroids in the 8 weeks prior to Screening
- Treatment with monoclonal antibody therapy, within 5-half-lives prior to Baseline
- Treatment with selected drugs known to have a substantial risk of neutropenia
- Absolute neutrophil count <2.0x10^9/L at Screening, or any documented history of absolute neutrophil count <2.0x10^9/L.
- Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m^2 at Screening
- Clinically significant abnormal laboratory or ECG values
- Other medically significant illness
- Use of any smoke or inhaled nicotine delivery device within 1 year prior to Screening
- Pregnant women or women breastfeeding
- Currently taking pramipexole or other dopamine agonists
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo BID
Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.
|
placebo twice daily oral dosing for up to 12 weeks
Other Names:
|
Active Comparator: 37.5 mg BID dexpramipexole
Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.
|
dexpramipexole twice daily oral dosing for up to 12 weeks
Other Names:
|
Active Comparator: 75 mg BID dexpramipexole
Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.
|
dexpramipexole twice daily oral dosing for up to 12 weeks
Other Names:
|
Active Comparator: 150 mg BID dexpramipexole
Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.
|
dexpramipexole twice daily oral dosing for up to 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Blood Absolute Eosinophil Count From Baseline to Week 12
Time Frame: Baseline, 12 Weeks
|
The primary endpoint of this study was the change in AEC from Baseline to Week 12 on a ratio scale.
The analysis used a mixed effects model repeated-measures (MMRM) with terms for log10 transformed baseline, GINA treatment step, treatment, visit, treatment by visit interaction, and log10 transformed baseline by visit interaction as fixed effects, and subject as a random effect.
An unstructured covariance matrix was used.
The response variable was the log10 transformed post-baseline value minus the log10 transformed baseline value.
The estimates of Geometric LS Means and their ratios were obtained by back transforming the corresponding estimates of LS means and their differences to the original scale.
|
Baseline, 12 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Pre-bronchodilator FEV1 (Liters) From Baseline to Week 12
Time Frame: Baseline, 12 Weeks
|
FEV1 is defined as the amount of air that can be forcibly exhaled from the lungs in the first second of a forced exhalation.
|
Baseline, 12 Weeks
|
Change in Asthma Control Questionnaire (ACQ-6) Score From Baseline to Week 12
Time Frame: Baseline, 12 Weeks
|
ACQ-6 is simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment.
The 6-point self-administered scale has items measuring asthma symptoms and rescue inhaler use.
The ACQ score is the mean of the questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).
The original protocol planned to analyze the ACQ-7 score.
As a result of FEV1 testing restrictions imposed on the study during the COVID-19 pandemic, the analysis was prospectively modified to the ACQ-6 score prior to database lock.
The ACQ-6 is a validated questionnaire and is identical to the ACQ-7, with the exception of FEV1 data that is also utilized in the ACQ-7 questionnaire total score calculation.
|
Baseline, 12 Weeks
|
Change in Post-bronchodilator FEV1 From Baseline to Week 12
Time Frame: Baseline, 12 Weeks
|
Post-bronchodilator FEV1 is defined as the amount of air that can be forcibly exhaled from the lungs in the first second of a forced exhalation, after treatment with inhaled albuterol.
|
Baseline, 12 Weeks
|
Change in Quality of Life, as Measured by the Asthma Quality of Life Questionnaire (AQLQ) From Baseline to Week 12
Time Frame: Baseline, 12 Weeks
|
The AQLQ is a 32-item asthma specific questionnaire designed to measure functional impairments that are most important to patients with asthma.
The 32 questions in the AQLQ are divided into four domains; activity limitations, symptoms, emotional function, and environmental stimuli.
Individual questions are equally weighted.
The overall AQLQ score is the mean of the responses to each of the 32 questions and ranges from 1 to 7. A score 7.0 indicates that the patient has no impairments due to asthma and score 1.0 indicates severe impairment.
|
Baseline, 12 Weeks
|
Number of Participants With Potentially Clinically Significant Hematology Results by Treatment Group Post Randomization Through Week 12
Time Frame: Immediately post-baseline up to Week 12
|
Number of Participants with Potentially Clinically Significant Hematology Results by Treatment Group.
Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group.
Patients are only counted once per criterion per laboratory test.
|
Immediately post-baseline up to Week 12
|
Number of Participants With Potentially Clinically Significant Blood Chemistry Results by Treatment Group Post Randomization Through Week 12
Time Frame: Immediately post-baseline up to Week 12
|
Number of Participants with Potentially Clinically Significant Blood Chemistry Results by Treatment Group.
Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group.
Patients are only counted once per criterion per laboratory test.
|
Immediately post-baseline up to Week 12
|
Number of Participants With Potentially Clinically Significant Urinalysis Results by Treatment Group Post Randomization Through Week 12
Time Frame: Immediately post-baseline up to Week 12
|
Number of Participants with Potentially Clinically Significant Urinalysis Results (glycosuria, ketonuria, or proteinuria) by Treatment Group.
Percentages based on number of patients with at least one non-missing post-baseline urinalysis value in each treatment group.
Patients are only counted once per criterion per laboratory test.
The number of participants with potential clinical important urinalysis findings at any post-baseline visit were reported.
|
Immediately post-baseline up to Week 12
|
Number of Participants With Potentially Clinically Significant Vital Signs Results by Treatment Group Post Randomization Through Week 12
Time Frame: Immediately post-baseline up to Week 12
|
Number of Participants with Potentially Clinically Significant Vital Signs Results by Treatment Group.
Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group.
Patients are only counted once per criterion per laboratory test.
|
Immediately post-baseline up to Week 12
|
Number of Participants With Potentially Clinically Significant ECG Results by Treatment Group Post Randomization Through Week 12
Time Frame: Immediately post-baseline up to Week 12
|
Number of Participants with Potentially Clinically Significant ECG Results by Treatment Group.
Percentages based on number of patients with at least one non-missing post-baseline value in each treatment group.
Patients are only counted once per criterion per laboratory test.
|
Immediately post-baseline up to Week 12
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Nasal Eosinophil Peroxidase (Presented as Ratio to Protein) From Baseline to Week 12
Time Frame: Baseline, Week 12
|
The EPX:protein ratio was used to normalize the EPX for the quantity of sample, yielding the values in ng EPX per mg protein.
The ratio of nasal Eosinophil Peroxidase to Protein is a biomarker for airway eosinophils.
A lower ratio to Baseline represents a lowering in airway eosinophilia, which is a marker of successful drug therapy.
|
Baseline, Week 12
|
Change in Blood Absolute Blood Basophil Count From Baseline to Week 12
Time Frame: Baseline, Week 12
|
The analysis used a mixed effects model repeated-measures MMRM with terms for baseline, GINA treatment step, treatment, visit, treatment by visit interaction, and baseline by visit interaction as fixed effects, and subject as a random effect.
An unstructured covariance matrix was used.
The response variable was the post-baseline value minus the baseline value.
Basophils were enumerated as part of the WBC automated differential performed by the Central Laboratory.
|
Baseline, Week 12
|
Change in Fractional Exhaled Nitric Oxide (FeNO) From Baseline to Week 12
Time Frame: Baseline, Week 12
|
FeNO is non-invasive biomarker of airway inflammation in asthma participants.
|
Baseline, Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 15, 2019
Primary Completion (Actual)
December 3, 2020
Study Completion (Actual)
March 2, 2021
Study Registration Dates
First Submitted
July 30, 2019
First Submitted That Met QC Criteria
August 2, 2019
First Posted (Actual)
August 6, 2019
Study Record Updates
Last Update Posted (Estimate)
April 13, 2023
Last Update Submitted That Met QC Criteria
April 11, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Hematologic Diseases
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Leukocyte Disorders
- Eosinophilia
- Hypereosinophilic Syndrome
- Asthma
- Pulmonary Eosinophilia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Dopamine Agonists
- Dopamine Agents
- Antioxidants
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Pramipexole
Other Study ID Numbers
- KNS-760704-AS201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States